Resources
- From ADCs to ABCs: A New Strategy for High-Capacity Targeted Drug Delivery
- RNA Therapies Update: Donidalorsen FDA Approved, Others Show Promise
- Advances in Antibody-Targeted Lipid Nanoparticles (Ab-LNPs) and Their Emerging Therapeutic Applications
- Antibody-Oligonucleotide Conjugates (AOCs): Recent Advances
- Molecular Glue-Antibody Conjugates (MACs)
- FDA Approval of Semaglutide for MASH - Other Promisiong Pipelines Ahead
- Key Advances in Breast Cancer Treatment: First Half of 2025
- BMS-986238: A New Macrocyclic Peptide-Based PD-L1 Inhibitor
- Camptothecin & Its Derivatives for Cancer Therapy
- FDA Approves First NASH Drug & Other Pipelines in Clinical Trials
